BF Biosciences appoints Farhan Rafique as new CEO

PAKISTAN – Pharmaceutical Industry

BF Biosciences Limited, a Pakistani pharmaceutical company, has announced a change in its top management, marking a new phase in the company’s leadership.

After successfully leading the company for nearly two decades, Mrs. Akhter Khalid Waheed, the founding Chairperson and Chief Executive Officer, has decided to step down from her role as CEO with effect from December 31, 2025. The Board of Directors, at its emergent meeting held on December 19, 2025, accepted her resignation and placed on record its appreciation for her significant contributions to the establishment, growth and long-term success of the company.

The Board acknowledged that under Mrs. Waheed’s leadership, BF Biosciences evolved into a reputable pharmaceutical organization, achieving key milestones and strengthening its market position.

On the recommendation of the Human Resource and Remuneration Committee, the Board also approved the appointment of Mr. Muhammad Farhan Rafique as Chief Executive Officer with effect from January 1, 2026.

Prior to his elevation, Mr. Farhan Rafique served as Chief Operating Officer of the company, where he played a key role in driving several strategic initiatives under the leadership of Mrs. Akhter Khalid Waheed. These included the company’s brownfield expansion, a successful initial public offering, and the implementation of digital transformation projects.

Mr. Farhan Rafique brings over 14 years of experience in the pharmaceutical industry and has held various leadership positions during his career. The company expressed confidence that his industry expertise and strategic vision will support BF Biosciences’ continued growth and innovation in the coming years. ——ER Web Desk

READ MORE